French drug major Sanofi reported Friday higher profit and net sales in its fourth quarter, mainly benefited by strong sales growth of Dupixent, despite weakness in Vaccines and General Medicines. Specialty Care advanced to the largest business unit by sales.
Looking ahead for fiscal 2022, Sanofi expects business earnings per share to grow low double-digit at constant exchange rates from prior year's business earnings per share of 6.56 euros.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.